Halozyme Therapeutics (HALO) Peer Comparison
$100.27
As on 13-Nov-2026 16:02EST
Market cap
$11,432 Mln
Revenue (TTM)
$1,802 Mln
P/E Ratio
25.2
P/B Ratio
97.2
Div. Yield
0 %
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
11,432 | 16,837 | 18,064 | 10,891 | 9,928 |
Revenue ($ Mln) |
1,802 | 2,497 | 1,208 | 102 | 1,428 |
Net Profit ($ Mln) |
485.42 | 885.14 | 890.37 | -349.47 | -155.46 |
Net Margin (%) |
26.93 | 35.45 | 73.69 | -341.87 | -10.89 |
RoE (%) |
-- | 46.96 | 88.40 | -22.16 | -26.57 |
Price to Earnings |
25.19 | 20.66 | 18.11 | -- | -- |
Price-To-Book |
97.15 | 9.18 | 10.44 | 6.72 | 15.76 |
Income Statement ($ Mln)
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,802.45 | 2,496.86 | 1,208.20 | 102.23 | 1,427.94 |
|
Cost of Revenue
|
319.65 | 93.32 | 113.42 | -74.16 | 129.12 |
|
Gross Profit
|
1,167.84 | 2,236.43 | 588.53 | 39.20 | 902.26 |
|
Operating Expenses
|
474.96 | 1,400.14 | 872.49 | 583.29 | 1,451.47 |
|
Operating Profit (EBIT)
|
1,007.84 | 1,003.39 | 222.29 | -404.89 | -152.65 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
655.01 | 1,065.84 | 271.18 | -349.70 | -155.46 |
|
Provision for Tax
|
169.59 | 180.70 | -619.19 | 0.00 | 0.00 |
|
Profit after Tax (Net Income)
|
485.42 | 885.14 | 890.37 | -349.47 | -155.46 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-55.24 | 1,833.83 | 1,525.85 | 1,614.53 | 626.94 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
3,052.50 | 267.78 | 384.05 | 63.02 | 353.20 |
|
Current Liabilities
|
476.09 | 411.88 | 558.37 | 89.72 | 454.24 |
|
Total Liabilities
|
2,525.32 | 2,844.42 | 1,302.02 | 1,742.81 | 1,259.59 |
Assets ($ Mln)
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,626.62 | 1,191.87 | 854.45 | 768.68 | 47.28 |
|
Current Assets
|
1,846.73 | 1,321.62 | 1,613.82 | 998.59 | 1,387.11 |
|
Total Assets
|
2,525.32 | 2,844.42 | 1,302.02 | 1,742.81 | 1,259.59 |
|
Total Debt*
|
3,250.30 | 162.20 | 455.38 | 76.60 | 354.22 |
|
Net Current Assets
|
1,370.64 | 909.75 | 1,037.87 | 908.87 | 932.87 |
Cashflow ($ Mln)
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
651.56 | 884.27 | 51.77 | -232.89 | -189.55 |
|
Cash Flow from Investing Activities
|
-545.81 | 350.44 | -8.15 | -521.06 | 32.32 |
|
Cash from Financing Activities
|
-85.17 | -969.59 | 34.89 | 990.71 | 255.98 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
15.61 | 32.82 | -30.01 | -24.09 | -31.49 |
|
ROE (%)
|
153.59 | 46.96 | 88.40 | -22.16 | -26.57 |
|
ROA (%)
|
13.85 | 28.91 | 34.34 | -23.06 | -8.54 |
|
EBIT Margin (%)
|
37.56 | 42.02 | 20.00 | -341.82 | -8.64 |
|
Net Margin (%)
|
26.93 | 35.45 | 73.69 | -341.87 | -10.89 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
45.03 | 9.12 | 86.87 | 133.74 | 92.80 |
|
EBIT Growth (%)
|
-11.34 | 23.13 | 260.53 | -18.50 | 54.59 |
|
Net Profit Growth (%)
|
-18.48 | 30.57 | 482.23 | -18.42 | 46.23 |
|
EPS Growth (%)
|
-17.34 | 38.78 | 453.25 | -2.42 | 53.71 |
|
Book Value Growth (%)
|
-110.94 | -7.57 | 878.06 | 48.81 | -25.69 |
Valuation Ratios
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
24.99 | 15.79 | -59.76 | -21.09 | -45.32 |
|
Price / Book Value
|
97.15 | 9.18 | 10.44 | 6.72 | 15.76 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
EV/EBITDA
|
16.67 | 14.81 | 70.48 | -29.66 | -76.35 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-53.31 | 0.00 | 0.25 | 0.00 | 0.54 |
|
Short term debt to equity ratio
|
-5.53 | 0.00 | 0.05 | 0.01 | 0.00 |
|
Current Ratio
|
3.88 | 3.21 | 2.89 | 11.13 | 3.05 |
|
Quick Ratio
|
3.60 | 3.14 | 2.29 | 11.13 | 2.78 |
|
Interest Coverage
|
30.70 | -- | 2.74 | -1,279.94 | -3.84 |
Operating Efficiency Ratios
| Halozyme Therapeutics (HALO) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Kymera Therapeutics (KYMR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
29.16 | 13.16 | 21.41 | 0.00 | 15.92 |
|
Asset Turnover
|
0.51 | 0.82 | 0.47 | 0.07 | 0.78 |
|
Receivable days
|
98.04 | 43.48 | 85.52 | 8.82 | 35.88 |
|
Inventory Days
|
254.12 | 96.17 | 1,056.70 | -- | 354.23 |
|
Payable days
|
24.86 | 147.97 | 331.01 | -- | 300.79 |
|
Cash Conversion Cycle
|
327.29 | -8.32 | 811.21 | -- | 89.33 |